Haemonetics Co. (NYSE:HAE) Short Interest Up 11.2% in March

Haemonetics Co. (NYSE:HAE - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 2,180,000 shares, a growth of 11.2% from the February 29th total of 1,960,000 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily volume of 444,100 shares, the days-to-cover ratio is presently 4.9 days.

Haemonetics Stock Performance

NYSE HAE traded down $0.56 during mid-day trading on Monday, reaching $84.79. 354,878 shares of the stock were exchanged, compared to its average volume of 458,010. The business's 50 day moving average is $77.28 and its 200-day moving average is $83.15. Haemonetics has a 1 year low of $70.74 and a 1 year high of $95.26. The company has a market capitalization of $4.31 billion, a P/E ratio of 34.47, a P/E/G ratio of 2.16 and a beta of 0.36. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period in the prior year, the firm posted $0.85 earnings per share. The firm's quarterly revenue was up 10.1% compared to the same quarter last year. On average, equities research analysts forecast that Haemonetics will post 3.95 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Haemonetics by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier's stock worth $482,017,000 after acquiring an additional 27,146 shares during the period. Kingdon Capital Management L.L.C. acquired a new position in Haemonetics during the third quarter worth $9,952,000. Lazard Asset Management LLC raised its position in Haemonetics by 114.2% during the third quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier's stock worth $3,452,000 after acquiring an additional 20,550 shares during the period. Los Angeles Capital Management LLC raised its position in Haemonetics by 1.1% during the third quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier's stock worth $4,753,000 after acquiring an additional 586 shares during the period. Finally, Eagle Asset Management Inc. raised its position in Haemonetics by 2.6% during the third quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier's stock worth $24,065,000 after acquiring an additional 6,828 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of recent analyst reports. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Barrington Research reaffirmed an "outperform" rating and issued a $105.00 price objective on shares of Haemonetics in a report on Tuesday, February 13th. Finally, TheStreet downgraded shares of Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.